The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

Buoyed by advancements in formulation technologies such as permeation enhancers, nanoparticle encapsulation and structural ...

The 6th TCR-based Therapies Summit returns as the only forum created solely for TCR experts pioneering best-in-class cell- ...

JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...

Despite the revolutionary impact of the original birth control pill, and the decades of medical innovation seen since, ...

For any company developing AI-powered solutions, the “why” should guide every decision. The technical sophistication of your ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...